SecBot SecBot

HKPD

Cellyan Biotechnology Co., Ltd
Nasdaq· Wholesale-Drugs, Proprietaries & Druggists' Sundries· Inc. E9· CIK 0002007702 Healthcare & Medical Devices
—
Market cap
$4.7M
Nano cap
Short interest
67.1K
≈0.1% of shares · −66.3%
Days to cover
1.0
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read BEARISH 3 reports · 90 days
Balance 1 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/3
Strongest BEARISH Cellyan Biotechnology announced a 1-for-20 reverse stock split effective October 26, 2026, aimed at…
All reports →

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 0 trimmed or exited.

  • Short sellersCOVERING

    Short interest −66.3% to 67.1K shares. 1.0 days to cover, ≈0.1% of shares.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGDOUBLED1,081$411.00

Quarterly 13F filings are due 45 days after each quarter ends.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Trading halt
🔒 Fresh data, subscribers only
Oct 21, 2026 SEC
Cellyan Biotechnology announced a 1-for-20 reverse stock split effective October 26, 2026, aimed at regaining…
6-K — Impact 5/10
Sep 23, 2026 SEC
Cellyan Biotechnology Co., Ltd reported the resignation of independent director Mike Yao Zhou and the appointment of…
6-K — Impact 2/10
Sep 23, 2026 SEC
Cellyan Biotechnology shareholders approved a 1-for-20 reverse share split and related charter amendments at an…
6-K — Impact 4/10
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
1,081 shares ($411.00)

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Sep 30, 2026
67,129
shares short
-66.3%
vs prior settlement
1.0
days to cover
≈0.1%
of shares outstanding
Trading halts
Oct 23, 2026Resumption ScheduledResumed
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 26, 2026
Trading halt
🔒 Fresh data, subscribers only
Oct 23, 2026
Trading halt
🔒 Fresh data, subscribers only
Oct 23, 2026
Trading halt
Trading Halt: HKPD — T1 (News Pending)
Cellyan Biotechnology Cl A OS | Market: NASDAQ | Code: T1 — News Pending
Jul 16, 2026
Announcement
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period
HONG KONG, July 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter…

SecBot reports

5 filings · 0 bullish · 2 bearish · 3 neutral
All HKPD filing & press-release reports (5)